Co-Authors
This is a "connection" page, showing publications co-authored by Rita Nanda and Frederick Howard.
Connection Strength
3.591
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
Score: 0.962
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.952
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
Score: 0.904
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 Feb 23.
Score: 0.248
-
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. Expert Rev Anticancer Ther. 2022 12; 22(12):1325-1331.
Score: 0.244
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.222
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.058